On the stock market since 2014, it operates in the world of health and science. It has 34 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 59% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 2,849% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 10 buys and 6 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $28.00 — 286% above today’s price.
Over the last 3 years, sales fell about 64% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 32/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 34/100.
On our five-subject report card, KYNB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KYNB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (49/100) says the stock isn’t cheap.